image credit- freepik
US-based Catalent and South Korea-based S.Biomedics have announced a strategic partnership to support the development and manufacturing of TED‑A9, S.Biomedics’ allogeneic pluripotent stem-cell-derived ventral midbrain–specific dopaminergic precursor cell therapy being developed for the treatment of Parkinson’s disease.
TED‑A9 represents S.Biomedics’ ambition to deliver a new class of regenerative medicine for patients with Parkinson’s disease. The programme reflects years of development using S.Biomedics’ proprietary targeted embryonic stem cell differentiation (TED) platform and builds on the company’s growing clinical pipeline of stem‑cell–based therapies.
Catalent will leverage its global network and deep expertise in cell therapy development, analytical services, and GMP manufacturing to support TED-A9. Catalent’s integrated platforms and iPSC/ESC experience position the company to accelerate programs like TED-A9 from early development through clinical and commercial launch.
“Initiating our first US clinical study, which is designed as a pivotal trial, represents a critical step toward delivering new treatment options to patients,” said Tony Kang, chief executive officer of S.Biomedics.
